澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

DIMERIX LTD

0.235

-0.005-2.08%

成交量：81.74萬

成交額：19.63萬

市值：1.41億

市盈率：-4.73

高：0.245

開：0.240

低：0.235

收：0.240

52周最高：0.665

52周最低：0.157

股本：6.00億

流通股本：4.68億

量比：0.83

換手率：0.17%

股息：- -

股息率：- -

每股收益(TTM):-0.050

每股收益(LYR):-0.050

淨資產收益率：-594.54%

總資產收益率：-29.36%

市淨率：-9.56

市盈率(LYR):-4.73

資料載入中...

總覽公司新聞資訊公告

概念

新冠治療股+0.93%

醫藥生物股+1.18%

資金流向

資金流入：

資金流出：

新聞資訊

Dimerix年度虧損達2980萬澳元，營收表現承壓

雲頂新耀達成重磅協議：預付款1000萬美元，開發及銷售里程碑總額高達3.3億美元，外加10%-15%銷售分成

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/DXB.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.235,"timestamp":1789452720000,"preClose":0.24,"halted":0,"volume":817391,"delay":0,"changeRate":-0.020833333333333353,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"未開盤","change":-0.005,"latestTime":"09-15 16:12:00 AEST","open":0.24,"high":0.245,"low":0.235,"amount":196289,"amplitude":0.041667,"askPrice":0.24,"askSize":5802,"bidPrice":0.235,"bidSize":226254,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.24,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":0.83241,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.24,"auctionPrice":0.235,"auctionVolume":2174,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452595590}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.83241,"shares":600396776,"dividePrice":0,"high":0.245,"amplitude":0.041667,"preClose":0.24,"low":0.235,"week52Low":0.157,"pbRate":"-9.56","psRate":"22.21","week52High":0.665,"institutionHeld":0,"latestPrice":0.235,"committee":0.949995,"eps":-0.0497,"divideRate":0,"volume":817391,"delay":0,"ttmEps":-0.0497,"open":0.24,"prevYearClose":0.55,"prevWeekClose":0.25,"prevMonthClose":0.28,"prevQuarterClose":0.205,"fiveDayClose":0.27,"twentyDayClose":0.295,"sixtyDayClose":0.205,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192319982","title":"Dimerix年度虧損達2980萬澳元，營收表現承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1192319982","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192319982?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 09:50","pubTimestamp":1787795440,"startTime":"0","endTime":"0","summary":"8月27日（路透社）——Dimerix Ltd（DXB.AX）最新财报显示，公司全年亏损额达2980万澳元。与此同时，该公司在报告期内的日常活动收入仅为700万澳元。这份业绩数据反映出公司当前面临的经营挑战，亏损规模与营收水平之间形成鲜明对比。市场投资者正密切关注该公司后续的财务策略与业务调整动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103772985","title":"雲頂新耀達成重磅協議：預付款1000萬美元，開發及銷售里程碑總額高達3.3億美元，外加10%-15%銷售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1103772985","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103772985?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 07:11","pubTimestamp":1781565072,"startTime":"0","endTime":"0","summary":"云顶新耀宣布达成一项具有里程碑意义的授权合作协议。根据协议条款，公司将获得一笔1000万美元的预付款，并有资格获得总额高达3.3亿美元的里程碑付款。这笔款项具体包括：高达3000万美元的开发里程碑款项，以及高达3亿美元的销售里程碑款项。此外，云顶新耀还将根据产品的全球净销售额，获得10%至15%的阶梯式特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","DXB.AU","BK1574","BK1583","BK7067","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DXB.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"新冠治療股","id":"package_au_concept_xgzlg","bkCode":"BK7501","changeRate":0.00931},{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.011805}]}}